Table 1 Characteristics of 290 population-based prostate cancer patients aged <55 years at diagnosis screened for BRCA2 mutations

From: Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer

 

1993–1996 ( n =162)

2002–2005 ( n =128)

Total case patients ( n =290)

Ascertainment period

N

%

N

%

N

%

Age at diagnosis (years)

 35–49

39

24.1

58

45.3

97

33.4

 50–54

123

75.9

70

54.7

193

66.6

Race

 Caucasian

154

95.1

103

80.5

257

88.6

 African-American

8

4.9

25

19.5

33

11.4

Jewish

 No

159

98.1

126

98.4

285

98.3

 Yes

3

1.9

2

1.6

5

1.7

Family history of prostate cancer

 None

111

68.5

71

55.5

182

62.8

 First-degree

33

20.4

40

31.3

73

25.2

 Second-degree only

18

11.1

17

13.3

35

12.1

Family history of breast cancer

 None

134

82.7

109

85.2

243

83.8

 First-degree

22

13.6

15

11.7

37

12.8

 Second-degree only

6

3.7

4

3.1

10

3.4

Family history of ovarian cancer

 None

157

96.9

123

96.1

280

96.6

 First-degree

2

1.2

3

2.3

5

1.7

 Second-degree only

3

1.9

2

1.6

5

1.7

Prostate cancer screeninga

 None

32

19.8

28

21.9

60

20.7

 DRE only

46

28.4

25

19.5

71

24.5

 PSA and DRE

84

51.9

75

58.6

159

54.8

Gleason score

 2–4

19

11.7

19

6.6

 5–6

82

50.6

69

53.9

151

52.1

 7 (3+4)

39

24.1

40

31.3

79

27.2

 7 (4+3)

9

5.6

11

8.6

20

6.9

 8–10

10

6.2

6

4.7

16

5.5

 Missing

3

1.9

2

1.6

5

1.7

Stage of cancer

 Localised

114

70.4

97

75.8

211

72.8

 Regional

40

24.7

29

22.7

69

23.8

 Distant

8

4.9

2

1.6

10

3.4

PSA at diagnosis (ng/ml) b

 0–3.9

26

16.1

29

22.7

55

19.0

 4.0–9.9

77

47.6

63

49.2

140

48.3

 10.0–19.9

21

12.9

15

11.7

36

12.4

20

19

11.7

11

8.6

30

10.3

 Missing

19

11.7

10

7.8

29

10.0

  1. aOne or more prostate-specific antigen (PSA) test or digital rectal exam (DRE) in the 5-year period before diagnosis date.
  2. bSerum prostate-specific antigen (PSA) level at diagnosis.